The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.
❓ Unknown
FDA approves new drug for advanced head and neck squamous cell carcinoma
Just now
November 18, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
The FDA approved Janssen Biotech's Rybrevant Faspro for treating advanced head and neck cancer in adults whose disease has progressed despite platinum-based chemotherapy and immunotherapy. This is a pharmaceutical development by a U.S. company with no direct connection to Iran.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
Just now •
Airstrikes on Kuwait and Bahrain Coincide with US Attack on Qeshm Island
2 min ago •
Russian Oil Exports Reach 4-Month Peak
10 min ago •